Published in Am Heart J on October 01, 1998
Anthracycline-induced cardiotoxicity. Ann Intern Med (1996) 4.31
Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. N Engl J Med (1995) 4.29
Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation (1996) 3.82
Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation (2000) 3.61
Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest (2001) 2.72
Association of revascularisation with low mortality in non-ST elevation acute coronary syndrome, a report from GUSTO IV-ACS. Eur Heart J (2004) 2.67
Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. Circulation (1997) 2.55
Cardiac troponin T and cardiac troponin I: relative values in short-term risk stratification of patients with acute coronary syndromes. GUSTO-IIa Investigators. Clin Chem (1998) 2.27
Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet (2001) 2.23
Myonecrosis after revascularization procedures. J Am Coll Cardiol (1998) 2.11
Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. The GUSTO-IIa Investigators. Circulation (1998) 2.09
Prognostic value of the admission electrocardiogram in acute coronary syndromes. JAMA (1999) 2.08
Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker. Eur Heart J (2002) 2.06
Metoclopramide. An updated review of its pharmacological properties and clinical use. Drugs (1983) 2.02
Risk stratification and therapeutic decision making in acute coronary syndromes. JAMA (2000) 1.99
Venous thromboembolism prophylaxis: do trial results enable clinicians and patients to evaluate whether the benefits justify the risk? Proceedings of an Ad Hoc Working Group Meeting. J Thromb Haemost (2013) 1.97
Bedside multimarker testing for risk stratification in chest pain units: The chest pain evaluation by creatine kinase-MB, myoglobin, and troponin I (CHECKMATE) study. Circulation (2001) 1.86
Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy. Circulation (2000) 1.79
Temporal creatine kinase curves in acute myocardial infarction. Implications of a good empiric fit with the log-normal function. Am J Clin Pathol (1993) 1.75
The current practice of intra-aortic balloon counterpulsation: results from the Benchmark Registry. J Am Coll Cardiol (2001) 1.74
Defining the optimal activated clotting time during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials. Circulation (2001) 1.70
Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest (1998) 1.67
Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial. J Am Coll Cardiol (2000) 1.63
Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT. Eur Heart J (2000) 1.62
Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes. Eur Heart J (2004) 1.59
Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation (1999) 1.59
Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries. J Am Coll Cardiol (1998) 1.55
Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation (2001) 1.54
Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation. Heart (2008) 1.54
Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up. J Am Coll Cardiol (2001) 1.51
Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial. Circulation (2001) 1.50
Lack of progress in cardiogenic shock: lessons from the GUSTO trials. Eur Heart J (2000) 1.50
Temporal evolution in the management of acute ST elevation myocardial infarction: the seven-year GUSTO experience from canada and the united states. The North American GUSTO-I and GUSTO-III investigators. Can J Cardiol (2000) 1.47
First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial. J Thromb Haemost (2005) 1.42
Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction. Dichotomous response as a function of age in the GUSTO V trial. Eur Heart J (2003) 1.42
Does the discharge ECG provide additional prognostic insight(s) in non-ST elevation ACS patients from that acquired on admission? Eur Heart J (2003) 1.40
Abciximab and atherosclerotic heart disease: use in percutaneous coronary intervention, acute coronary syndromes and acute myocardial infarction. Int J Clin Pract (2003) 1.40
Evaluation of the effects of aspirin combined with angiotensin-converting enzyme inhibitors in patients with coronary artery disease. Am J Med (2000) 1.39
Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial. Int J Clin Pract (2009) 1.39
Should glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? Yes. J Thromb Haemost (2004) 1.39
New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. Am Heart J (2000) 1.39
Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. Circulation (1997) 1.38
Serum myoglobin for the early non-invasive detection of coronary reperfusion in patients with acute myocardial infarction. Eur Heart J (1996) 1.38
Depressed platelet status in an elderly patient with hemorrhagic stroke after thrombolysis for acute myocardial infarction. GUSTO-III Investigators. Stroke (1998) 1.37
Cell adhesion molecules in coronary artery disease. J Am Coll Cardiol (1994) 1.35
Abciximab reduces mortality in diabetics following percutaneous coronary intervention. J Am Coll Cardiol (2000) 1.33
Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIb. PARAGON-A and GUSTO IIb Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute Global Organization Network. J Am Coll Cardiol (2001) 1.27
Local intraluminal infusion of biodegradable polymeric nanoparticles. A novel approach for prolonged drug delivery after balloon angioplasty. Circulation (1996) 1.23
Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion. J Am Coll Cardiol (2001) 1.22
Is all unstable angina the same? insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I). The CAVEAT-Investigators. Am Heart J (1999) 1.20
Abnormal cardiac enzyme responses after strenuous exercise: alternative diagnostic aids. Br Med J (Clin Res Ed) (1982) 1.19
Percutaneous revascularization of chronic coronary occlusions: an overview. J Am Coll Cardiol (1995) 1.17
Intravenous thrombolysis in acute myocardial infarction. Chest (2001) 1.13
A randomized, repeat-dose, pharmacodynamic and safety study of an antidote-controlled factor IXa inhibitor. J Thromb Haemost (2008) 1.13
Neointimal hyperplasia after arterial injury is increased in a rat model of non-insulin-dependent diabetes mellitus. Circulation (2001) 1.12
Rapid platelet-function assay: an automated and quantitative cartridge-based method. Circulation (1999) 1.12
Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II. J Am Coll Cardiol (1999) 1.11
Prior aspirin use predicts worse outcomes in patients with non-ST-elevation acute coronary syndromes. PURSUIT Investigators. Platelet IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy. Am J Cardiol (1999) 1.10
Glycoprotein IIb/IIIa inhibitors: therapeutic applications in acute ST-segment elevation myocardial infarction. Am Heart J (2000) 1.07
The use of glycoprotein IIb/IIIa inhibitor therapy in acute ST-segment elevation myocardial infarction: current practice and future trends. Am J Cardiol (2000) 1.07
Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy. Circulation (2001) 1.07
Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators. Circulation (1995) 1.03
Abciximab readministration: results of the ReoPro Readministration Registry. Circulation (2001) 1.01
Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention. JAMA (2001) 1.01
Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol (1995) 1.01
Use of intraaortic balloon counterpulsation in patients presenting with cardiogenic shock: observations from the GUSTO-I Study. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol (1997) 1.00
Predictors of 90-day outcome in patients stabilized after acute coronary syndromes. Eur Heart J (2003) 1.00
Changes in standard electrocardiographic ST-segment elevation predictive of successful reperfusion in acute myocardial infarction. Am J Cardiol (1990) 0.99
Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. J Am Coll Cardiol (2000) 0.98
Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. Am Heart J (2000) 0.97
Age and outcome after acute coronary syndromes without persistent ST-segment elevation. Am Heart J (2000) 0.95
Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. Circulation (1995) 0.95